The effect of Obstructive Sleep Apnoea (OSA) and its treatment with Continuous Positive Airways Pressure (CPAP) on lipid metabolism

Woolcock Institute of Medical Research0 个研究点目标入组 29 人开始时间: 2005年8月2日最近更新: 2022年8月9日

适应症

试验速览

暂无简介。

•Body Mass Index (BMI) less than or equal to 35. Fasting Triglycerides < 4mmol/L. Respiratory Disturbance Index (RDI) of >= 25 and Oxygen Desaturation Index (ODI) >=20

•Stage 1 1. Clinically significant co morbidity, including any unstable cardiovascular, gastrointestinal, metabolic, pulmonary (e.g., asthma, COPD), renal, neurological, hepatic, hematologic, immunologic, endocrine, psychiatric illness and/or neoplastic disease based on Principal Investigator judgment. 2. Patients who are on fibrate (lipid lowering) medications. 3. Fasting triglycerides > 4mmol/l 4. Patients unable to read and understand the Patient Information Sheets or Consent Forms. Stage 2 1. Claustrophobia. 2. Any in vivo Ferro-magnetic material such as a pacemaker, Neuro stimulator, Cochlear Implants, aneurysm clip, metal implants, shrapnel injuries, ever worked with metal, ever had metal in their eye or if they had any surgery.
•Stage 3 1. Clinically significant co morbidity, including any unstable cardiovascular, gastrointestinal, metabolic, pulmonary (e.g., asthma, COPD), renal, neurological, hepatic, hematologic, immunologic, endocrine, psychiatric illness and/or neoplastic disease based on Principal Investigator judgment. 2. Patients unable to read and understand the Patient Information Sheets or Consent Forms. 3. Medication exclusions - Beta blockers and Beta 2 agonists.

发起方